Physiological and biological characterization of smokers with and without COPD

Nveed Chaudhary, Karsta Luettich, Michael J Peck, Elena Pierri, Loyse Felber-Medlin, Gregory Vuillaume, Patrice Leroy, Julia Hoeng, Manuel C Peitsch, Nveed Chaudhary, Karsta Luettich, Michael J Peck, Elena Pierri, Loyse Felber-Medlin, Gregory Vuillaume, Patrice Leroy, Julia Hoeng, Manuel C Peitsch

Abstract

Chronic obstructive pulmonary disease (COPD) is a common inflammatory airway disease predominantly associated with cigarette smoking, and its incidence is increasing worldwide. According to the Global Initiative for Obstructive Lung Disease (GOLD) guidelines, spirometry is used to diagnose the disease. However, owing to its complexity, spirometry alone may not account for the multitude of COPD phenotypes or the early, asymptomatic lung damage seen in younger smokers. In addition, suitable biomarkers enabling early diagnosis, guiding treatment and estimating prognosis are still scarce, although large scale 'omics analyses have added to the spectrum of potential biomarkers that could be used for these purposes. The aim of the current study was to comprehensively profile patients with mild-to-moderate COPD and compare the profiles to i) a group of currently smoking asymptomatic subjects, ii) a group of healthy former smokers, and iii) a group of healthy subjects that had never smoked. The assessment was conducted at the molecular level using proteomics, transcriptomics, and lipidomics and complemented by a series of measurements of traditional and emerging indicators of lung health (ClinicalTrials.gov identifier: NCT01780298). In this data note, we provide a comprehensive description of the study population's physiological characteristics including full lung function, lung appearance on chest computed tomography, impulse oscillometry, and exercise tolerance and quality of life (QoL) measures.

Keywords: COPD; biomarker; gas transfer; impulse oscillometry; lung function; lung sound analysis.

Conflict of interest statement

Competing interests: NIC, KL, MJP, EP, LFM, GV, PL, MCP and JH are full-time employees of Philip Morris Products SA, Philip Morris International. KL, MJP, EP, LFM, GV, PL, MCP and JH declared no other potential conflicts of interest with respect to the research, authorship, and/or publication of this article. NIC discloses royalties related to the sales of OFEV (nintedanib; Boehringer Ingelheim), which is marketed for the treatment of pulmonary fibrosis.

Figures

Figure 1.. CONSORT flow diagram of the…
Figure 1.. CONSORT flow diagram of the progress through the phases of this study (i.e. enrolment, allocation, visits/measurements, and data analysis).

References

    1. Diaz-Guzman E, Mannino DM: Epidemiology and Prevalence of Chronic Obstructive Pulmonary Disease. Clin Chest Med. 2014;35(1):7–16. 10.1016/j.ccm.2013.10.002
    1. WHO: World health statistics 2008.World Health Organization;2008.
    1. Agusti A, Calverley PM, Celli B, et al. : Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res. 2010;11(1):122. 10.1186/1465-9921-11-122
    1. Celli BR, Halbert RJ, Isonaka S, et al. : Population impact of different definitions of airway obstruction. Eur Respir J. 2003;22(2):268–273. 10.1183/09031936.03.00075102
    1. Coxson HO, Leipsic J, Parraga G, et al. : Using Pulmonary Imaging to Move Chronic Obstructive Pulmonary Disease beyond FEV1. Am J Respir Crit Care Med. 2014;190(2):135–144. 10.1164/rccm.201402-0256PP
    1. Celli BR, Decramer M, Wedzicha JA, et al. : An official American Thoracic Society/European Respiratory Society statement: research questions in COPD. Eur Respir Rev. 2015;24(136):159–172. 10.1183/16000617.00000315
    1. Rooney C, Sethi T: Biomarkers for precision medicine in airways disease. Ann N Y Acad Sci. 2015;1346(1):18–32. 10.1111/nyas.12809
    1. Titz B, Sewer A, Schneider T, et al. : Alterations in the sputum proteome and transcriptome in smokers and early-stage COPD subjects. J Proteomics. 2015;128:306–320. 10.1016/j.jprot.2015.08.009
    1. Titz B, Luettich K, Leroy P, et al. : Alterations in Serum Polyunsaturated Fatty Acids and Eicosanoids in Patients with Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD). Int J Mol Sci. 2016;17(9): pii: E1583. 10.3390/ijms17091583
    1. Talikka M, Martin F, Sewer A, et al. : Mechanistic evaluation of the impact of smoking and chronic obstructive pulmonary disease on the nasal epithelium. Clin Med Insights Circ Respir Pulm Med. 2017; In press. 10.1177/1179548417710928
    1. Schulz KF, Altman DG, Moher D, et al. : CONSORT 2010 Statement: Updated guidelines for reporting parallel group randomised trials. J Clin Epidemiol. 2010;63(8):834–840. 10.1016/j.jclinepi.2010.02.005
    1. Miller MR, Hankinson J, Brusasco V, et al. : Standardisation of spirometry. Eur Respir J. 2005;26(2):319–338. 10.1183/09031936.05.00034805
    1. Quanjer PH, Tammeling GJ, Cotes JE, et al. : Lung volumes and forced ventilatory flows. Eur Respir J. 1993;6(Suppl 16):5–40. 10.1183/09041950.005s1693
    1. Bergstresser T, Ofengeim D, Vyshedskiy A, et al. : Sound transmission in the lung as a function of lung volume. J Appl Physiol (1985). 2002;93(2):667–674. 10.1152/japplphysiol.00050.2002
    1. Wells AU, King AD, Rubens MB, et al. : Lone cryptogenic fibrosing alveolitis: a functional-morphologic correlation based on extent of disease on thin-section computed tomography. Am J Respir Crit Care Med. 1997;155(4):1367–1375. 10.1164/ajrccm.155.4.9105081
    1. Wells AU, Desai SR, Rubens MB, et al. : Idiopathic Pulmonary Fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med. 2003;167(7):962–969. 10.1164/rccm.2111053
    1. Hansell DM, Rubens MB, Padley SP, et al. : Obliterative bronchiolitis: individual CT signs of small airways disease and functional correlation. Radiology. 1997;203(3):721–726. 10.1148/radiology.203.3.9169694
    1. Roberts HR, Wells AU, Milne DG, et al. : Airflow obstruction in bronchiectasis: correlation between computed tomography features and pulmonary function tests. Thorax. 2000;55(3):198–204. 10.1136/thorax.55.3.198
    1. McInnis KJ, Balady GJ: Comparison of submaximal exercise responses using the Bruce vs modified Bruce protocols. Med Sci Sports Exerc. 1994;26(1):103–107. 10.1249/00005768-199401000-00017
    1. Ware JE, Jr, Sherbourne CD: The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473–483.
    1. Mahler DA, Wells CK: Evaluation of clinical methods for rating dyspnea. Chest. 1988;93(3):580–586. 10.1378/chest.93.3.580
    1. Celli BR, Cote CG, Marin JM, et al. : The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004;350(10):1005–1012. 10.1056/NEJMoa021322
    1. Lopez-Campos JL, Cejudo P, Marquez E, et al. : Modified BODE indexes: Agreement between multidimensional prognostic systems based on oxygen uptake. Int J Chron Obstruct Pulmon Dis. 2010;5:133–40. 10.2147/COPD.S8827
    1. Cardoso F, Tufanin AT, Colucci M, et al. : Replacement of the 6-min walk test with maximal oxygen consumption in the BODE Index applied to patients with COPD: an equivalency study. Chest. 2007;132(2):477–482. 10.1378/chest.07-0435
    1. Vuillaume G, Chaudhary N, Luettich K, et al. : Dataset 1 in: Data of physiological measurements and quality of life in subjects with mild to moderate COPD compared to asymptomatic current smokers, former smokers and never-smokers. F1000Research. 2017.
    1. Vuillaume G, Chaudhary N, Luettich K, et al. : Dataset 2 in: Data of physiological measurements and quality of life in subjects with mild to moderate COPD compared to asymptomatic current smokers, former smokers and never-smokers. F1000Research. 2017.
    1. Vuillaume G, Chaudhary N, Luettich K, et al. : Dataset 3 in: Data of physiological measurements and quality of life in subjects with mild to moderate COPD compared to asymptomatic current smokers, former smokers and never-smokers. F1000Research. 2017.
    1. Vuillaume G, Chaudhary N, Luettich K, et al. : Dataset 4 in: Data of physiological measurements and quality of life in subjects with mild to moderate COPD compared to asymptomatic current smokers, former smokers and never-smokers. F1000Research. 2017.
    1. Vuillaume G, Chaudhary N, Luettich K, et al. : Dataset 5 in: Data of physiological measurements and quality of life in subjects with mild to moderate COPD compared to asymptomatic current smokers, former smokers and never-smokers. F1000Research. 2017.
    1. Vuillaume G, Chaudhary N, Luettich K, et al. : Dataset 6 in: Data of physiological measurements and quality of life in subjects with mild to moderate COPD compared to asymptomatic current smokers, former smokers and never-smokers. F1000Research. 2017.
    1. Vuillaume G, Chaudhary N, Luettich K, et al. : Dataset 7 in: Data of physiological measurements and quality of life in subjects with mild to moderate COPD compared to asymptomatic current smokers, former smokers and never-smokers. F1000Research. 2017.
    1. Vuillaume G, Chaudhary N, Luettich K, et al. : Dataset 8 in: Data of physiological measurements and quality of life in subjects with mild to moderate COPD compared to asymptomatic current smokers, former smokers and never-smokers. F1000Research. 2017.
    1. Chaudhary N, Luettich K, Peck MJ, et al. : Dataset 9 in: Physiological and biological characterization of smokers with and without COPD. F1000Research. 2018.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する